Skip to main content

Table 1 Summarized characteristics of IRE cohort patients (N = 60)

From: MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

Characteristics N(%)
Age yr, median (range) 55 (36–81)
BRCA 1/2 status
Wild Type 54 (90%)
Mutated 6 (10%)
Hystology
Serous carcinoma 45 (75.0%)
Clear cell carcinoma 4 (6.7%)
Mixed serous and clear cell carcinoma 1 (1.6%)
Poorly differentiated carcinoma 6 (10.0%)
Not otherwise specified carcinoma 4 (6.7%)
Disease setting (FIGO Stage)
Metastatic (Stage IV) 11 (18.3%)
Adjuvant (Stage I - IIIB) 27 (45.0%)
Neoadjuvant (IIIC) 22 (36.7%)
First systemic treatment
Carboplatin + Paclitaxel 54 (90%)
Carboplatin + Paclitaxel + Bevacizumab 4 (6.8%)
Carboplatin + Docetaxel 1 (1.6%)
Cisplatin + Gemcitabine 1 (1.6%)